Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
127.06
-1.37 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
February 06, 2023
Neurocrine also topped fourth-quarter revenue expectations on Monday.
Via
Investor's Business Daily
Earnings Scheduled For February 6, 2023
February 06, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.
Via
Benzinga
Neurocrine Biosciences Earnings Preview
February 03, 2023
Via
Benzinga
Why Voyager Therapeutics Stock Is Sinking This Week
January 20, 2023
Investors are taking profits on this red-hot stock this week.
Via
The Motley Fool
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via
Benzinga
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
January 25, 2023
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Via
MarketBeat
7 A-Rated Stocks to Buy for Less Than $25
January 24, 2023
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Via
InvestorPlace
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
January 13, 2023
Sharp Tesla price cuts and some notable earnings were in focus.
Via
Investor's Business Daily
Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal
January 09, 2023
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.
Via
InvestorPlace
Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies
January 09, 2023
Via
Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
December 25, 2022
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Via
Benzinga
Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally
December 17, 2022
UnitedHealth is among medical stocks holding key support.
Via
Investor's Business Daily
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
December 07, 2022
Via
Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
November 16, 2022
Neurodegenerative disorders could mean big bucks for some biotechs.
Via
Investor's Business Daily
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
November 14, 2022
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...
Via
Benzinga
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Looking Into Neurocrine Biosciences's Return On Capital Employed
November 09, 2022
According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90...
Via
Benzinga
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
November 04, 2022
A mixed jobs report and heavy earnings swung stocks.
Via
Investor's Business Daily
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat
November 01, 2022
The company raised its guidance for Ingrezza sales in 2022.
Via
Investor's Business Daily
Neurocrine Biosciences: Q3 Earnings Insights
November 01, 2022
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Earnings Scheduled For November 1, 2022
November 01, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
4 Analysts Have This to Say About Neurocrine Biosciences
September 26, 2022
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
September 26, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.